Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Employees - 1017,
CEO - Mr. Jan Moller Mikkelsen,
Sector - Healthcare,
Country - DK,
Market Cap - 9.73B
Altman ZScore(max is 10): 4.16, Piotroski Score(max is 10): 4, Working Capital: $152998000, Total Assets: $1179495000, Retained Earnings: $0, EBIT: -256118354, Total Liabilities: $1285201000, Revenue: $363641000
- Current Price $162.60 - Analyst Target Price $213.92| Ticker | ASND |
| Index | - |
| Curent Price | 162.60 |
| Change | 1.34% |
| Market Cap | 9.73B |
| Average Volume | 511.02K |
| Income | -409.98M |
| Sales | 391.88M |
| Book Value/Share | -1.83 |
| Cash/Share | 9.68 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | - |
| Moving Avg 20days | 6.60% |
| Moving Avg 50days | 5.72% |
| Moving Avg 200days | 18.02% |
| Shares Outstanding | 59.84M |
| Earnings Date | Feb 12 AMC |
| Inst. Ownership | 106.69% |
| Price/Earnings | - |
| Forwad P/E | 78.69 |
| PE Growth | - |
| Price/Sales | 24.83 |
| Price/Book | - |
| Price/Cash | 16.79 |
| Price/FCF | - |
| Quick Ratio | 0.84 |
| Current Ratio | 1.17 |
| Debt/Equity | - |
| Return on Assets | -38.44% |
| Return on Equity | - |
| Return on Investment | -152.65% |
| Gross Margin | 84.31% |
| Ops Margin | -77.23% |
| Profit Margin | -104.62% |
| RSI | 59.17 |
| BETA(β) | 0.41 |
| From 52week Low | 46.37% |
| From 52week High | -4.00% |
| EPS | -7.13 |
| EPS next Year | 2.07 |
| EPS next Qtr | -1.64 |
| EPS this Year | 44.17% |
| EPS next 5 Year | - |
| EPS past 5 Year | -6.13% |
| Sales past 5 Year | 185.30% |
| EPS Y/Y | 22.96% |
| Sales Y/Y | 36.09% |
| EPS Q/Q | 58.45% |
| Sales Q/Q | 25.27% |
| Sales Surprise | 46.46% |
| EPS Surprise | 34.47% |
| ATR(14) | 8.15 |
| Perf Week | -1.49% |
| Perf Month | 2.73% |
| Perf Quarter | 26.83% |
| Perf Year | 12.27% |
| Perf YTD | 18.11% |
| Target Price | 213.92 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer